The estimated Net Worth of Mitchell Gold is at least $16.9 Milione dollars as of 8 May 2024. Mitchell Gold owns over 13,245 units of Alpine Immune Sciences Inc stock worth over $7,097,648 and over the last 7 years he sold ALPN stock worth over $8,210,564. In addition, he makes $1,555,930 as Executive Chairman of the Board e Chief Executive Officer at Alpine Immune Sciences Inc.
Mitchell has made over 14 trades of the Alpine Immune Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 13,245 units of ALPN stock worth $100,000 on 8 May 2024.
The largest trade he's ever made was selling 445,262 units of Alpine Immune Sciences Inc stock on 17 September 2021 worth over $4,212,179. On average, Mitchell trades about 42,020 units every 74 days since 2017. As of 8 May 2024 he still owns at least 109,245 units of Alpine Immune Sciences Inc stock.
You can see the complete history of Mitchell Gold stock trades at the bottom of the page.
Dr. Mitchell H. Gold M.D. serves as Executive Chairman of the Board, Chief Executive Officer of the Company. He has served as our executive chairman, chief executive officer and a member of our board of directors since the completion of the merger of Nivalis Therapeutics, Inc. (which we refer to as Nivalis) and Alpine Immune Sciences, Inc. (which we refer to as Private Alpine) in July 2017 and prior to the merger served as Private Alpine’s chief executive officer since June 2016 and as Private Alpine’s executive chairman and member of Private Alpine’s board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012, Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000, Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin.
As the Executive Chairman of the Board e Chief Executive Officer of Alpine Immune Sciences Inc, the total compensation of Mitchell Gold at Alpine Immune Sciences Inc is $1,555,930. There are no executives at Alpine Immune Sciences Inc getting paid more.
Mitchell Gold is 53, he's been the Executive Chairman of the Board e Chief Executive Officer of Alpine Immune Sciences Inc since 2017. There are 6 older and 8 younger executives at Alpine Immune Sciences Inc. The oldest executive at Alpine Immune Sciences Inc is Dr. Jan L. Hillson Ph.D., M.D., 67, who is the Sr. VP of Clinical Devel..
Mitchell's mailing address filed with the SEC is C/O ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE, WA, 98102.
Over the last 7 years, insiders at Alpine Immune Sciences Inc have traded over $91,012,519 worth of Alpine Immune Sciences Inc stock and bought 8,061,426 units worth $69,477,679 . The most active insiders traders include Peter A. Thompson, Advisors Llc Orbi Med Capit... e James N Topper. On average, Alpine Immune Sciences Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,201,670. The most recent stock trade was executed by Stanford L Peng on 8 May 2024, trading 271,792 units of ALPN stock currently worth $668,608.
founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.
Alpine Immune Sciences Inc executives and other stock owners filed with the SEC include: